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Abstract
Background: Microbiological criteria for diagnosing nontuberculous mycobacterial pulmonary disease (NTM-PD)
include positive culture results from at least two separately expectorated sputum specimens or one bronchial
washing or lavage. However, the clinical similarities and differences between patients diagnosed by these two
methods remain unclear. We compared clinical features and prognoses of patients with NTM-PD diagnosed from
both specimen types.
Methods: We analysed data from patients who participated in the Seoul National University Hospital NTM-PD cohort
(ClinicalTrials.gov identifier: NCT01616745). Baseline demographics, symptoms, radiographic findings, disease
progression, and treatment responses were summarized and compared between patients diagnosed from sputum
specimens and patients diagnosed from bronchoscopic specimens.
Results: Three hundred forty-seven patients were included in the analyses. Of these, 279 (80.4%) were diagnosed
from two separately expectorated sputum specimens, and 68 (19.6%) were diagnosed from bronchoscopic specimens.
Patients diagnosed from sputum specimens had more frequent and severe cough, sputum, postnasal drip, and high
St. George’s Respiratory Questionnaire scores. However, the extent and severity of the radiographic lesions, disease
progression, and treatment responses were similar for both groups. Further analysis based on the following three
groups (sputum culture positive, sputum culture negative/bronchoscopy, and scanty sputum/bronchoscopy groups)
suggested that the scanty sputum/bronchoscopy group appeared to have the worst prognosis in terms of both time
to progression and time to culture conversion.
Conclusions: Although some symptoms and quality of life were worse in patients with NTM-PD diagnosed from sputum
specimens, their prognoses were similar to those of patients diagnosed by bronchoscopic specimen. We recommend
bronchoscopic sampling for patients in whom NTM-PD is suspected clinically or radiographically, especially those who
have no or scanty sputum.
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Background
The incidence and prevalence of nontuberculous myco-
bacterial (NTM) pulmonary disease (PD) is increasing
worldwide [1–8]. In South Korea, the prevalence of
NTM infections has also increased rapidly: 9.4/100,000
persons in 2009 to 36.1/100,000 persons in 2016 [9].
Increases in NTM-PD lead to more hospitalizations,
higher costs, and increased mortality [10].
Diagnosing NTM-PD relies on combining clinical and
microbiological criteria [11, 12]. Clinical criteria include
pulmonary symptoms and nodular or cavitary opacities on
chest imaging, with appropriate exclusion of other diagno-
ses. To fulfil the microbiological criteria, positive cultures
from at least two separately expectorated sputum specimens
or one bronchial washing or lavage specimen are required.
However, it remains unclear whether the clinical features
differ between NTM patients diagnosed by the two
methods [11]. Diagnosis using sputum may imply the
presence of productive sputum, which may represent more
severe form of NTM-PD. Furthermore, the current guide-
lines do not propose any clinical evidence about the diag-
nostic criteria of NTM-PD [11, 12]. This study compared
clinical characteristics and prognoses between patients
diagnosed from either two sputum specimens or from one
bronchoscopic specimen.
Methods
Study participants and design
Patients aged ≥20 years with NTM-PD who participated
in the ongoing prospective cohort, Seoul National
University Hospital NTM cohort (ClinicalTrials.gov
identifier: NCT01616745), which commenced on 1
July 2011, were included in this analysis [13–16].
NTM-PD was diagnosed in accordance with the criteria
proposed by the American Thoracic Society/Infectious Dis-
eases Society of America (ATS/IDSA) and British Thoracic
Society (BTS) guidelines [11, 12]. Bronchoscopic sampling
was performed in patients who could not expectorate or in
patients with suspected NTM-PD but negative mycobac-
terial culture. Patients who withdrew consent, were pre-
viously treated for NTM-PD, or had poor compliance
during treatment (delaying visits for > 1month) were
excluded. All patients provided written informed consent
before registering. Baseline data were retrieved on 11 April
2017, and the follow-up data on disease progression and
culture conversion were retrieved on 26 January 2018.
Baseline evaluations
Baseline demographics were recorded at the time of
enrolment. Cough and sputum symptoms were divided
into four categories: none, sometimes, often, and almost
every day for coughing; none, ≤3 days per week, ≥4 days
per week, and almost every day for sputum. Dyspnoea
scales were divided into five categories (0–4) per the
modified Medical Research Council dyspnoea scale [17].
Other complaints such as haemoptysis, postnasal drip,
fever, and weight loss were also recorded. Anxiety and
depression were evaluated using the Hospital Anxiety
and Depression Scale [18]. Overall respiratory health
and quality of life were assessed utilizing St. George’s
Respiratory Questionnaire [19].
Baseline serum laboratory tests were performed, and
pulmonary function was tested for forced expiratory vol-
ume in 1 second (FEV1), forced vital capacity (FVC),
FEV1/FVC ratio, and diffusing capacity for carbon mono-
xide. Computed tomography (CT) scans of the chest were
obtained upon diagnosis. Radiographic subtype was classi-
fied as nodular bronchiectatic form or upper lobe cavitary
form. When the subtype was unclassifiable, it was allo-
cated into either subtype based on the dominant feature
for further analysis in this study. In addition, radiographic
NTM-PD severity was assessed by two board-certified
radiologists, who were blinded to the patients’ clinical
data, using a previously introduced scoring system [20].
The extents of bronchiectasis (maximum score of 9),
cellular bronchiolitis (maximum score of 6), cavities
(maximum score of 9), nodules (maximum score of 3),
and consolidation (maximum score of 3) were considered
in calculating the total score (maximum score of 30).
Follow-up evaluations
Participants were followed every 3 to 6months. On each
visit, participants were examined by investigators who ob-
tained sputum specimens for acid-fast bacilli smears and
mycobacterial cultures and took simple chest radiographs.
CT scans of the chest were repeated within one year after
enrolment, then every two years, and radiographic severity
was reassessed upon disease progression using the scoring
system described above. Once treatment was initiated,
participants were followed every 4–8 weeks. On each visit,
participants were examined, sputum specimens were
obtained and simple chest radiographs were taken.
Microbiological assessment
Acid-fast bacilli smears and mycobacterial cultures were
performed following the recent guidelines [11]. All cul-
tures were grown in both solid Ogawa media (Shinyang
Diagnostics, Seoul, South Korea) and the BACTEC MGIT
960 system (Becton-Dickinson and Co., Sparks, MD, US).
NTM species were identified by sequencing of the 16S
ribosomal RNA gene using the algorithm specified in the
Clinical and Laboratory Standards Institute guidelines
[13], as well as sequencing of the rpoB gene [21]. rpoB
gene sequencing and patterns of clarithromycin resistance
were checked to differentiate between M. abscessus sub-
species abscessus and M. abscessus subspecies massiliense
[22]. M. abscessus subspecies taxonomy was in accordance
with recent suggestions [23]. Patients were considered to
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have mixed NTM species infections if an NTM species
other than the original species was isolated at least twice
during the follow-up period.
Definitions
Patients were divided into two groups per the diagnostic
method upon enrolment: either isolation of NTM from
≥2 sputum specimens (sputum group) or isolation of
NTM from a bronchoscopic specimen (bronchoscopy
group). When NTM were isolated from both sputum and
bronchoscopic specimens, patients were classified by the
test that yielded NTM sooner. For the sputum group, the
date of the second positive sputum culture was considered
the date of diagnosis. For the bronchoscopy group, the
date of the bronchoscopy that yielded a positive NTM
culture was considered the date of diagnosis.
Disease progression was defined as physician recom-
mendation for treatment initiation based on clinical
and radiographic deterioration, as used previously by us
and other researchers [16, 24, 25]. Decision to initiate
treatment was made by the on-duty physicians based on
clinical (e.g., new-onset haemoptysis) or radiographic
deterioration (e.g., cavity formation) for each patient. Four
physicians (CSM, LJ, LCH, and YJJ) managed the patients
and discussed the need to initiate treatment.
NTM-PD was treated as per recent guidelines [11, 12].
Clarithromycin-sensitive Mycobacterium avium complex
(MAC)-PD was treated with a macrolide, ethambutol,
and rifampicin using a thrice weekly or daily schedule,
and an injectable aminoglycoside was considered in
patients with a severe disease extent. M. abscessus-PD
was initially treated with a combination of azithromycin,
aminoglycoside, and imipenem (or cefoxitin) for the first
3 weeks, and aminoglycoside administration (3 to 5 times
per week) was continued for at least 3 more months with
azithromycin during the continuation phase. Clofazimine
has been used for both MAC-PD and M. abscessus-PD
patients who were refractory to treatment or resistant
to clarithromycin. When treating patients with mixed
NTM infections, we targeted the most frequently isolated
NTM species.
Culture conversion was defined as at least three conse-
cutive negative results from sputum mycobacterial cultures
after initiating treatment and adopted as a parameter for
treatment response [26]. The collection day of the first
sputum with a negative culture was regarded as the day of
culture conversion [26, 27].
Statistical analysis
Categorical variables were summarized as numbers with
percentages and compared using a chi-square test or
Fisher’s exact test. Continuous variables are presented
as the median with interquartile range (IQR) and ana-
lysed using the Mann-Whitney U test. The Wilcoxon
signed-rank test was also used to evaluate changes in
NTM-PD radiographic severity scores. To estimate the
probability of disease progression and culture conversion
after treatment, Kaplan-Meier survival analyses with a
log-rank test were used. To estimate hazard ratios (HRs)
with 95% confidence intervals (CIs) for each potential
variable affecting the study outcomes, we utilized a Cox
proportional hazards model. Covariates with P-values less
than 0.05 were further included in a multivariate model to
calculate the adjusted HR of each variable. All statistical
analyses were performed using Stata, version 13.0 (Stata
Corp., College Station, TX, US).
Results
Baseline characteristics
On the date of extraction of initial data (11 April 2017),
372 patients were enrolled in the cohort. Of these,
patients who did not fulfil the diagnostic criteria for
NTM-PD (n = 11), had withdrawn consent (n = 10),
started treatment before diagnosis (n = 3), or had poor
compliance (n = 1) were excluded. Finally, 347 patients
with NTM-PD were included in the analysis. Of these,
279 (80.4%) were diagnosed from two consecutive sputum
specimens obtained at a median interval of 3.2 months
(IQR 0.3, 0.7), whereas 68 (19.6%) were diagnosed by
examination of single bronchoscopic specimens. The
reasons for undergoing bronchoscopic sampling were
as follows: could not expectorate or had too little
sputum (47 patients) or suspected NTM-PD but
negative acid-fast staining or mycobacterial culture
(21 patients) on ≥2 sputum specimens.
Sex and age were similarly distributed between both
groups. Patients in the sputum group smoked more ciga-
rettes (median 22.5 pack-years [IQR: 15, 33.8]) than did the
bronchoscopy group (median 13.8 [IQR: 5, 20], P = 0.046).
History of tuberculosis treatment was more common in
the sputum group than in the bronchoscopy group (41.6%
vs. 22.1%, P = 0.008). Nodular bronchiectatic form was
the main radiographic subtype in both groups: 90.0
and 94.1% in the sputum and bronchoscopy groups,
respectively (P = 0.288). NTM species were similarly
distributed in both groups. MAC was the most common
(n = 243), and M. abscessus the second most common
(n = 63). M. abscessus consists of 32 strains of M. abscessus
subsp. abscessus and 31 of M. abscessus subsp. massiliense.
Twelve of 32 strains of M. abscessus subsp. abscessus
(37.5%) and 26 strains of 31M. abscessus subsp. massiliense
(83.9%) were clarithromycin-susceptible. The rate of smear
positivity did not differ according to the type of specimen:
16.9 and 22.1% were positive in the sputum and bron-
choscopy group, respectively (P = 0.314) (Table 1).
FEV1 was lower in the sputum group than in the bron-
choscopy group, although this was not statistically signi-
ficant (2.12 L vs.2.33 L, P = 0.06). Other laboratory test
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details revealed no significant differences between the two
groups [see Additional file 1: Table S1].
Differences in subjective symptoms upon NTM-PD diagnosis
Coughing and sputum were more severe among patients
in the sputum group, in which, 76 patients (27.2%) had
coughing “almost every day”, compared with 11 (16.2%)
in the bronchoscopy group (P = 0.002). Likewise, 140
patients (50.2%) in the sputum group had sputum “almost
every day”, compared with only 14 (20.6%) in the bron-
choscopy group (P < 0.001). Patients in the sputum group
had more severe respiratory symptoms and worse quality
Table 1 Baseline characteristics of 347 patients diagnosed with nontuberculous mycobacterial pulmonary disease using different
diagnostic methods
Variables Total patients N = 347 Sputum group n = 279 Bronchoscopy group n = 68 P-value
Sex, female 215 (62.0) 176 (63.1) 39 (57.4) 0.383
Age, years 66 (59, 74) 67 (59, 74) 66 (58, 74) 0.509
Smoking history 0.985
Never smoker 258 (74.4) 208 (74.6) 50 (73.5)
Former smoker 79 (22.8) 63 (22.6) 16 (23.5)
Current smoker 10 (2.9) 8 (2.9) 2 (2.9)
Pack-years for smokers 20 (10, 30) 22.5 (15, 33.8) 13.8 (5, 20) 0.046
History of tuberculosis 131 (37.8) 116 (41.6) 15 (22.1) 0.008
Smear positivity of specimen on diagnosis 62 (17.9) 47 (16.9) 15 (22.1) 0.314
Underlying disease
COPD 32 (9.2) 28 (10.0) 4 (5.9) 0.288
GERD 27 (7.8) 23 (8.3) 4 (5.9) 0.583
Cancer 22 (6.3) 18 (6.5) 4 (5.9) 0.863
Diabetes mellitus 22 (6.3) 16 (5.7) 6 (8.8) 0.349
Occupational status 0.583
Office work 53 (15.3) 42 (15.1) 11 (16.2)
Housewife 53 (15.3) 41 (14.7) 12 (17.7)
Professional practitioner 41 (11.8) 33 (11.8) 8 (11.8)
Self-employment 38 (11.0) 32 (11.5) 6 (8.8)
Unemployed 21 (6.1) 18 (6.5) 3 (4.4)
Construction worker 14 (4.0) 13 (4.7) 1 (1.5)
Service industry 14 (4.0) 12 (4.3) 2 (2.9)
Radiographic subtype 0.288
Nodular bronchiectatic form 315 (90.8) 251 (90.0) 64 (94.1)
Upper lobe cavitary form 32 (9.2) 28 (10.0) 4 (5.9)
NTM species 0.184
Mycobacterium avium 129 (37.2) 97 (34.8) 32 (47.1)
Mycobacterium intracellulare 110 (31.7) 91 (32.6) 19 (27.9)
Other MAC 4 (1.2) 4 (1.4) 0 (0.0)
Mycobacterium abscessus subsp. abscessus 32 (9.2) 25 (9.0) 7 (10.3)
Mycobacterium abscessus subsp. massiliense 31 (8.9) 28 (10.0) 3 (4.4)
Mycobacterium kansasii 7 (2.0) 6 (2.2) 1 (1.5)
Mycobacterium fortuitum 3 (0.9) 3 (1.1) 0 (0.0)
Others 13 (3.7) 10 (3.6) 3 (4.4)
Mixed infectiona 12 (3.5) 12 (4.3) 0 (0.0)
Unknownb 6 (1.7) 3 (1.1) 3 (4.4)
Values are presented as number (percentage) or median (interquartile range)
Abbreviations: COPD chronic obstructive pulmonary disease, GERD gastroesophageal reflux disease, NTM nontuberculous mycobacteria, MAC
Mycobacterium avium complex
a More than two NTM species isolated at least twice each during the follow-up period until the start of treatment. bThe results of species identification for
NTM are missing
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of life overall than those in the bronchoscopy group,
showing higher St. George’s Respiratory Questionnaire
scores (median 17.6 vs. 9.9, respectively, P < 0.001). The
frequencies of other symptoms, including dyspnoea,
haemoptysis, fever, weight loss, anxiety, and depression
were similar between the groups (Table 2).
Disease progression among patients with NTM-PD
Patients were followed for a median of 2.9 years (IQR:
1.6, 4.6) after their NTM-PD diagnosis: median 3.0 years
(IQR:1.8, 4.8) for the sputum group vs. 2.1 years (IQR:
1.1, 3.7) for the bronchoscopy group. Among the 347
patients, 133 (38.3%) experienced disease progression. In
the sputum group, disease progression manifested as
clinical deterioration in 17 patients (15.3%), radiographic
deterioration in 54 (48.7%), and both in 40 (36.0%). The
ratios were similar in the bronchoscopy group, namely 4
(18.2%), 11 (50.0%), and 7 (31.8%) patients, respectively,
in the above three categories (P = 0.907).
Time to progression for NTM-PD was similar
between the sputum and bronchoscopy groups (log-rank
P = 0.772) (Fig. 1a). In the sputum group, one-year and
two-year progression rates were 19.0 and 28.0%, while in
the bronchoscopy group, they were 16.2 and 26.5%. Times
to progression according to diagnostic methods were simi-
lar between MAC-PD (log-rank P = 0.987) and M. absces-
sus-PD (log-rank P = 0.455) patients. Younger age (HR
0.97; 95% CI 0.96–0.99 per year) and the upper lobe cavi-
tary disease form (HR 3.16; 95% CI 1.78–5.62 compared
with the nodular bronchiectatic form) were identified
as independent factors for earlier disease progression.
However, diagnostic method (sputum vs. bronchos-
copy) was not a predictor of earlier disease progression;
the HR of the bronchoscopy group was 0.82 with a 95%
CI 0.48–1.38 compared with the sputum group (Table 3).
The baseline radiographic severity score showed a
median of 8 (IQR: 6, 10), which was elevated to median 10
(IQR: 7, 14) with disease progression (P < 0.001 by paired
t-test). These scores ranged from median 8 (IQR: 6, 10) to
10 (IQR: 7, 14) for the sputum group (P < 0.001) and from
median 8 (IQR: 6, 11) to 10 (IQR: 7, 14) for the bronchos-
copy group (P = 0.002).
Table 2 Differences in assessed symptoms of nontuberculous mycobacterial pulmonary disease between patients diagnosed using
different methods upon enrolment
Variables Total patients N = 347 Sputum group n = 279 Bronchoscopy group n = 68 P-value
Cough 0.002
None 129 (37.2) 90 (32.3) 39 (57.4)
Sometimes 77 (22.2) 67 (24.0) 10 (14.7)
Often 54 (15.6) 46 (16.5) 8 (11.8)
Almost everyday 87 (25.1) 76 (27.2) 11 (16.2)
Sputum < 0.001
None 105 (30.3) 66 (23.7) 39 (57.4)
≤ 3 days per week 53 (15.3) 43 (15.4) 10 (14.7)
≥ 4 days per week 35 (10.1) 30 (10.8) 5 (7.4)
Almost everyday 154 (44.4) 140 (50.2) 14 (20.6)
mMRC dyspnoea scale 0.581
0 131 (37.9) 102 (36.7) 29 (42.7)
1 197 (56.9) 159 (57.2) 38 (55.9)
2 15 (4.3) 14 (5.0) 1 (1.5)
3 2 (0.6) 2 (0.7) 0 (0.0)
4 1 (0.3) 1 (0.4) 0 (0.0)
Haemoptysis 63 (18.2) 50 (17.9) 13 (19.1) 0.864
Postnasal drip 92 (26.5) 84 (30.1) 8 (11.8) 0.007
SGRQ score 16.1 (8.1, 30.6) 17.6 (9.5, 32.4) 9.9 (4.9, 20.2) < 0.001
Fever 39 (11.2) 32 (11.5) 7 (10.3) 0.850
Weight loss 30 (8.7) 25 (9.0) 5 (7.4) 0.800
Anxiety scale 5 (2, 7) 5 (2, 7) 5 (2, 7) 0.632
Depression scale 5 (2, 7) 5 (2, 8) 5 (3, 7) 0.716
Values are presented as number (percentage) or median (interquartile range)
Abbreviations: mMRC modified Medical Research Council, SGRQ St. George’s Respiratory Questionnaire
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Treatment response among NTM patients in whom
treatment was initiated
The 133 patients who experienced disease progression
were further analysed. Of these, 131 patients began
treatment, while two (1.5%) refused, and 78 (58.6%)
remained on treatment at the time of data retrieval. The
median treatment duration was 1.4 years (IQR: 0.7, 1.7)
in all patients who initiated treatment, with medians
of 1.5 years (IQR 0.8, 1.8) for the sputum group and
1.2 years (IQR 0.2, 1.4) for the bronchoscopy group.
Fig. 1 Comparison of disease progression and time to culture conversion between patients diagnosed from sputum specimens and patients
diagnosed from bronchoscopic specimen. a Probability of progression-free survival. b Probability of culture conversion after treatment
Table 3 Factors associated with disease progression of nontuberculous mycobacterial lung disease
Variables Unadjusted HR (95% CI) Adjusted HR (95% CI)
Age, by each year 0.97 (0.96–0.99) * 0.97 (0.96–0.99) *
Sex, female 1.38 (0.96–2.00) –
Body mass index, by 1 kg/m2 0.89 (0.83–0.95) * 0.94 (0.87–1.01)
Smoking
Never smoker Reference –
Former smoker 0.72 (0.47–1.18) –
Current smoker 1.82 (0.80–4.15) –
Haemoglobin, by 1 g/dL 0.83 (0.73–0.95) * 0.89 (0.75–1.06)
Platelet, by 1000/μL 1.00 (1.00–1.01) * 1.00 (1.00–1.00)
Total protein, by 1 g/dL 1.88 (1.22–2.89) * 1.57 (0.97–2.52)
Total bilirubin, by 1 mg/dL 0.40 (0.18–0.85) * 0.42 (0.17–1.04)
SGRQ score, by each score 1.01 (1.00–1.02) –
FEV1, by 1 L 1.00 (1.00–1.00) –
FVC, by 1 L 1.00 (1.00–1.00) –
DLCO, by 1% 0.99 (0.98–1.00) * 0.99 (0.98–1.01)
Computed tomography type
Nodular bronchiectatic form Reference Reference
Upper lobe cavitary form 3.69 (2.30–5.94) * 3.16 (1.78–5.62) *
Diagnostic method
NTM culture on two sputum specimens Reference Reference
NTM culture on bronchoscopic specimen 0.93 (0.59–1.48) 0.82 (0.48–1.38)
* Indicates statistical significance with P-value< 0.05
Abbreviations: SGRQ St. George’s Respiratory Questionnaire, FEV1 forced expiratory volume in 1 second, FVC forced vital capacity, DLCO diffusing capacity of the
lungs for carbon monoxide
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Time to culture conversion was compared between the
13 patients in the bronchoscopy group whose subsequent
sputum cultures yielded NTM and who therefore started
treatment and the 109 patients in the sputum group who
also started treatment. Culture conversion of sputum was
achieved in 7 of 13 patients in the bronchoscopy group
(53.9%) within a median of 1.8 months (IQR: 1.0, 6.4) and
in 71 of 109 patients in the sputum group (65.1%)
within a median of 1.8 months (IQR: 0.5, 4.3). Time to
culture conversion did not differ significantly between
the sputum and bronchoscopy groups (log-rank P = 0.869)
(Fig. 1b). Time to culture conversion according to
diagnostic method also did not differ between patients
with MAC-PD (log-rank P = 0.440) and M. abscessus-PD
(log-rank P = 0.267).
Comparison of groups according to reasons for
undergoing bronchoscopy
Because there were two different categories of reasons for
undergoing bronchoscopy, namely negative sputum cul-
ture and scanty sputum, further analysis was performed
based on the following three groups: sputum culture posi-
tive, sputum culture negative/bronchoscopy, and scanty
sputum/bronchoscopy groups (Table 4).
Although time to progression did not differ signifi-
cantly between these three groups (log-rank P = 0.250)
(Fig. 2a) and nor did time to culture conversion after
treatment (log-rank P = 0.324) (Fig. 2b), the prognosis
appeared to be worst in the scanty sputum/bronchos-
copy group.
Discussion
Due to the ubiquitous nature of NTM species, multiple
positive culture results from expectorated sputum
should be analysed [28]. In addition, more than two
MAC isolates were reported to be linked to development
of new cavities or progression of infiltration [29]. Con-
versely, specimens from bronchoscopic washing or bron-
choalveolar lavage taken from disease-specific sites may
lower the contamination risk and increase the specificity
of the culture result [30]. Therefore, guidelines recom-
mend that single NTM isolates from bronchoscopic
specimens satisfy microbiological criteria [11, 12]. BTS
guidelines recommend CT-directed bronchial washing
for NTM suspects who cannot expectorate sputum or
whose sputum is consistently culture-negative [12].
In this prospective cohort study, clinical features and
prognoses were compared for NTM-PD patients diag-
nosed from two different microbiological criteria (two
sputum specimens or one bronchoscopic specimen).
Although some symptoms and quality of life were worse
in patients diagnosed from sputum, times to disease
progression and culture conversion with treatment were
similar between both groups.
The similar prognoses despite worse symptoms found
in this study for patients diagnosed from sputum re-
quires further explanation. Sputum group patients more
frequently complained of symptoms related to sputum
production or expectoration (e.g., cough, sputum, post-
nasal drip). However, other symptoms not directly asso-
ciated with sputum yield (e.g., haemoptysis, fever, weight
loss) were similar between both groups. Results of other
tests, including pulmonary function and radiographic se-
verity, were also similar. Finally, disease progression and
culture conversion with treatment were similar between
both groups. These findings suggest that the specimen
collection method reflects the sputum accessibility, ra-
ther than the overall disease severity. Our results sup-
port the microbiologic criteria for NTM-PD suggested
by the current ATS/IDSA and BTS guidelines [11, 12].
It is interesting to note the differences between the
sputum culture negative/bronchoscopy and scanty spu-
tum/bronchoscopy groups. Our analysis suggested that
the scanty sputum/bronchoscopy group appeared to
have the worst prognosis in terms of both time to pro-
gression and time to culture conversion; however, this
difference was not statistically significant. This finding
suggests that bronchoscopy should be performed more
actively in patients with possible NTM-PD who are not
producing sputum.
In our institution, bronchoscopic sampling, rather than
sputum induction, was performed for patients who could
not expectorate sputum for the diagnosis of NTM-PD.
Although the induction of sputum is considered as one of
the sampling methods for patients with suspicion of
NTM-PD as well as pulmonary tuberculosis, the superior-
ity of sputum induction over routine sputum examination
is questionable [31]. In addition, the optimal methodology
for sputum induction has not been established yet [11,
12]. Furthermore, sputum induction was reported to be
inferior to bronchoscopy for the diagnosis of pulmonary
tuberculosis [32]. Given the decent lung function of our
patients in bronchoscopy group, performing bronchos-
copy rather than sputum induction to obtain specimen
could be regarded as standard care [33].
The strength of this study was that the analyses were
based on the prospective cohort, which adopted not only
interviews and questionnaires, but objective measures
including pulmonary function tests and chest CT scans.
Pulmonary function and CT scores taken at baseline
evaluation confirmed that both groups were similar in
disease severity. Furthermore, disease progression, deter-
mined by the on-duty physician during follow-up, was
also confirmed by worsening lesions on the CT, which
was scored by board-certified radiologists who were
blinded to the patients’ clinical data.
In this study, only culture conversion was adopted as
the treatment response, which could be a limitation.
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Table 4 Characteristics of 347 patients diagnosed with nontuberculous mycobacterial pulmonary disease according to three groups
of patients







Sex, female 176 (63.1) 10 (47.6) 29 (61.7) 0.371
Age, years 67 (59, 74) 64 (60, 76) 66 (57, 73) 0.593
Smoking history 0.919
Never smoker 209 (74.6) 15 (71.4) 35 (74.5)
Former smoker 63 (22.6) 5 (23.8) 11 (23.4)
Current smoker 9 (2.9) 1 (4.8) 1 (2.1)
History of tuberculosis 116 (41.6) 6 (28.6) 9 (19.2) 0.034
Smear-positive upon diagnosis 47 (16.9) 2 (9.5) 13 (27.7) 0.311
Underlying disease
COPD 28 (10.0) 3 (14.3) 1 (2.1) 0.092
GERD 23 (8.2) 1 (4.8) 3 (6.4) 0.712
Cancer 18 (6.5) 3 (14.3) 1 (2.1) 0.155
Diabetes mellitus 16 (5.7) 4 (19.1) 2 (4.3) 0.069
Radiographic subtype 0.475
Nodular bronchiectatic 251 (90.0) 19 (90.5) 45 (95.7)
Upper lobe cavitary 29 (10.0) 2 (9.5) 2 (4.3)
Cough 0.004
None 90 (32.3) 8 (38.1) 31 (66.0)
Sometimes 67 (24.0) 5 (23.8) 5 (10.6)
Often 46 (16.5) 3 (14.3) 5 (10.6)
Almost everyday 76 (27.2) 5 (23.8) 6 (12.8)
Sputum < 0.001
None 66 (23.7) 13 (61.9) 26 (55.3)
≤ 3 days per week 43 (15.4) 2 (9.5) 8 (17.0)
≥ 4 days per week 30 (10.8) 1 (4.8) 4 (8.5)
Almost everyday 140 (50.2) 5 (23.8) 9 (19.2)
mMRC dyspnoea scale 0.806
0 102 (36.7) 7 (33.3) 22 (46.8)
1 159 (57.2) 14 (66.7) 24 (51.1)
2 14 (5.0) 0 (0.0) 1 (2.1)
3 2 (0.7) 0 (0.0) 0 (0.0)
4 1 (0.4) 0 (0.0) 0 (0.0)
Haemoptysis 50 (17.9) 5 (23.8) 8 (17.0) 0.792
Postnasal drip 84 (30.1) 3 (14.3) 5 (10.6) 0.015
SGRQ score 17.6 (9.5, 32.4) 12.6 (6.9, 21.0) 9.2 (4.1, 17.5) < 0.001
Fever 32 (11.5) 3 (14.3) 4 (8.5) 0.807
Weight loss 25 (9.0) 1 (4.8) 4 (8.5) > 0.999
Anxiety scale 5 (2, 7) 4 (2, 7) 5 (2, 6) 0.872
Depression scale 5 (2, 8) 5 (3, 7) 5 (3, 7) 0.917
Values are presented as number (percentage) or median (interquartile range)
Abbreviations: COPD chronic obstructive pulmonary disease, GERD gastroesophageal reflux disease, mMRC modified medical research council, SGRQ
St. George’s Respiratory Questionnaire
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Because follow-up durations were relatively short after
initiating treatment, other treatment outcomes such as
‘microbiological cure’ or ‘treatment failure’ could not be
compared for this study. Long-term observation of
these patients could elucidate treatment responses
more clearly. Another limitation of this study is that rates
of both disease progression and culture conversion may
have been affected by the different follow-up durations in
different groups. Follow-up durations varied according to
the time of enrolment.
Conclusions
In conclusion, disease progression and treatment response
were similar between patients with NTM-PD diagnosed
from sputum specimens and those diagnosed from bron-
choscopic specimens, despite some symptoms and quality
of life being worse in patients diagnosed from sputum.
We recommend bronchoscopic sampling for patients in
whom NTM-PD is suspected clinically or radiographically,
especially those who have no or scanty sputum.
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